Purpose: Moderate deep inspiration breath-hold (mDIBH), using an Active Breathing Control device, has been used in our clinic since 2002 to reduce cardiac dose for patients receiving left-sided breast irradiation. We report our routine use of the mDIBH technique in clinically localized breast cancer, treated to the intact breast, reconstructed breast, or chest wall.
A s breast conserving therapy has become the predominant therapeutic option for early-stage breast cancer, the majority of women with this diagnosis undergo some form of radiotherapy as a component of their treatment. Radiotherapy has been shown in a number of large, prospective, randomized trials to reduce the risk of local recurrence of breast cancer. 1, 2 In addition, several studies have shown the benefits of radiotherapy in the postmastectomy setting. 3, 4 In addition, recent meta-analyses have also shown its benefits in terms of improving breast cancer survival. 5 However, certain radiotherapy techniques may contribute to patient mortality from other causes. Namely, increased cardiac radiation exposure from the deep edge of the tangential beams, normally used in the adjuvant therapy of left-sided breast cancer, has been shown to be associated with increased risks of heart disease and cardiac mortality. 5 Respiratory motion studies in the past have shown that deep inspiration results in increased distance between the heart and the left anterior chest wall. This has been shown in prior studies to reduce the volume of the heart and, specifically, of left ventricular myocardium receiving doses of radiation, which is likely to be of biological significance. 6, 7 Additional studies evaluating myocardial perfusion using single-photon emission computed tomography (SPECT) imaging have correlated perfusion defects with regions of increased myocardial radiation exposure. 8 Although such studies have not yet been able to correlate such findings with clinical endpoints such as coronary artery disease, myocardial infarction, or cardiac mortality, such demonstrable changes, when combined with data from population studies and prospective trials with longterm follow-up, provide compelling reasons to pursue techniques to reduce myocardial exposure during left-sided breast irradiation.
Prior data published from our institution have shown the efficacy of Active Breathing Control (ABC) in terms of the reduction of irradiated myocardium as well as the practical feasibility of its implementation in the clinic. 6, 9 We present in this report, our updated experience with ABC in the adjuvant irradiation of early-stage, left-sided breast cancer patients. resulted in improvements in cardiac dose when compared with free-breathing (FB) plans and were included in this study (William Beaumont Hospital Human Investigation Committee 1997-082). All patients included had early localized breast cancer (The American Joint Committee on Cancer stages I, II,  and III) , left-sided breast cancer (40% of which required regional nodal irradiation). Initially, patient eligibility required that Z2% of the contoured heart volume on standard, FB, planning computed tomography (CT) scan should be receiving a dose of >30 Gy (cardiac V 30 Z2%). Patients had to demonstrate a comprehension of the rationale of this treatment such that an optimal level of compliance could be attained. In the initial stages of this study, it was found that patients who had problems with claustrophobia had a more difficult time complying with the ABC treatment protocol, and consequently, severe claustrophobia became an exclusion criterion for this trial. After the enrolment of the first 5 patients in this study (all less than age 55), no specific age criteria were implemented provided patients could show a minimum comfort level with the ABC device to allow for efficient delivery of daily treatment. Ultimately, after enroling the first 25 participants, patients were screened for possible ABC treatment at the treating physician's discretion, taking into account patient age, chemotherapy use, and Trastuzumab use.
ABC Hardware
The ABC device has been described at length in previous publications but will be briefly reviewed. 10 The same device was used during both the planning and treatment sessions and is the active breathing coordinator device commercially available through Elekta Oncology Systems. The device consists of a digital spirometer to record the patients' real-time breathing trace and a balloon valve that is triggered to automatically inflate when the patients inspire to their preset mDIBH level. This allows for a predictable, consistent level of chest wall expansion with each mDIBH. A nose clip is used to prevent leakage and allow for accurate measurement of inspiratory volume. The trace is viewed on a laptop computer by radiation therapy (RT) staff outside the treatment room, and a prism glass positioned above the patient allows for viewing of their respiratory trace and anticipated duration of the breathhold. The details of several minor modifications made to the ABC system to facilitate RT delivery are given in a prior publication. 6 
Study Design
Following initial consultation at which time the patients' candidacy for adjuvant radiotherapy was verified, all patients underwent an initial, FB planning CT scan using Alpha Cradle immobilization. A prospective treatment plan was then generated incorporating medial and lateral nondivergent tangential beams to treat the entire left breast. A step-and-shoot intensitymodulated radiotherapy (IMRT) approach that has been described at length previously in the literature was used to optimize dose homogeneity within the breast. 11 For those patients requiring regional nodal irradiation, the third field encompassing the supraclavicular field was delivered, typically by a monoisocentric technique. Cardiac volume was defined within the treatment planning system and a dose-volume histogram (DVH) analysis was performed.
Those who enroled in this study underwent an initial training session. The patients were placed in their Alpha Cradle in the treatment position and connected to the ABC device. Their maximal inspiratory capacity was recorded according to the ABC spirometry software. A comfortable level of breath-hold was then determined, which would be used throughout the treatment course. This was generally set at approximately 75% maximal inspiratory capacity and was termed mDIBH. Once patients were able to show that they could comfortably maintain this level of breath-hold for 20 to 25 seconds, they were deemed candidates for this treatment.
Patients then underwent repeat planning CT scan in mDIBH while connected to the ABC device. The planning process was then repeated using unopposed tangential beams to treat the entire left breast ± the supraclavicular field by implementation of a step-and-shoot IMRT technique. Treatment plans were prepared with both the FB and mDIBH scans by the same dosimetrist using identical guidelines for delineation of target volumes and organs at risk to assure that target coverage was identical between the 2 plans. A verification simulation was performed with the patient connected to the ABC device to confirm the geometric parameters generated during the virtual CT simulation.
Treatment Delivery
Treatment was administered daily with a median whole breast total dose of 45 Gy, implementing ABC for each treatment. Patients were coached by RT staff on a daily basis, typically to perform 2 normal inspiratory/expiratory cycles before initiating mDIBH. The radiation therapist would initiate treatment once the patient achieved mDIBH as documented by the digital respiratory trace. Each medial and lateral nondivergent tangential beam was delivered over 2 to 3 breathholds, whereas the third beam addressing the supraclavicular field, if necessary, was delivered during an additional 1 to 2 breath-holds. Treatments were typically supplemented by direct en face electron boost to a dose of Z60 Gy. ABC was not used during the boost portion of treatment.
Data Generation and Analysis
All planning and dosimetric evaluations were performed on the Pinnacle 3 treatment planning system v. 8.0 (Phillips Healthcare, Andover, MI). The biopsy cavity, breast/chest wall, regional lymphatics (if applicable), and ipsilateral/ contralateral lung, as well as heart, were contoured on both mDIBH and FB plans. Calculated DVHs were compared between both techniques for each of the aforementioned volumes. Paired sample t tests were performed using SPSS v. 17 (SPSS Inc., Chicago, IL) to compare parameters between treatment techniques.
RESULTS

Patients and Treatments
Eighty-seven patients, median age of 49 years (range, 29 to 70 y), are included for analysis ( Table 1 ). The median tumor size was 1.8 cm and the majority of patients had rT2 invasive tumors of the upper outer quadrant. In addition, patients were nearly evenly split into those having involvement of 1 or more lymph nodes and those with a negative sentinel lymph node biopsy. Table 2 shows the treatment characteristics of the patients, with approximately two thirds of which received RT as a part of breast conserving therapy. Further, 66% received adjuvant chemotherapy with cardiotoxic agents, 45% with anthracycline-based regimens and 9% with trastuzumab.
shown in the DVH (Fig. 2) , there is significantly less dose delivered to the heart with the mDIBH plan compared with the FB plan. The delivered plan through mDIBH results in significant decrease in the heart volume treated: 0.79 versus 2.3 mL (P < 0.0001) as well as mean heart dose: 2.5 versus 4.2 Gy (P < 0.0001) as shown in Table 3 . All volumetric parameters evaluated, V 30 , V 25 , V 20 , V 15 , V 10 , and V 5 , were also significantly decreased as compared with the FB plan. In addition, for 34% of the patients, the V 25 was 0% for the delivered mDIBH plan.
Lung Doses
In addition to cardiac dose reductions, mDIBH also significantly reduced lung dose, as shown by the DVH for the mDIBH plan versus that of the FB plan ( Fig. 3 ). As displayed in Table 4 , the mDIBH technique decreased the ipsilateral mean lung dose from 9.1 to 7.9 Gy (P < 0.001) as well as the volume of lung treated from 8.6 to 7.8 mL (P < 0.001). There were also statistically significant decreases in the left lung V 20 , V 15 , V 10 , and V 5 volumes when evaluating the delivered mDIBH plan versus the FB plan.
DISCUSSION
Several population-based mortality studies have shown an increase in cardiac mortality in the setting of patients irradiated for left-sided breast cancer. [12] [13] [14] [15] [16] A recent analysis of 42,000 women treated in 78 randomized trials using RT for breast cancer has shown small but significant reductions in breast cancer mortality within the first 10 years after treatment, primarily because of excess mortality due to heart disease (rate ratio, 1.27; SE, 0.07; 2P = 0.0001) and lung cancer (rate ratio, 1.78; SE, 0.22; 2P = 0.0004). 5 These small improvements in survival seem to diminish with time because of the late effects of RT on adjacent normal tissues. It has long been speculated that one of the primary factors responsible for the detrimental effect of RT on survival was cardiac toxicity related to RT exposure. Adding concern is that most breast cancer patients are now also receiving cardiotoxic systemic therapy. As increased use of postmastectomy RT can be expected, given that 3 recent studies 3,4 showed improved survival with RT for all patients with positive lymph nodes, it is vital that new RT techniques be developed that can provide improved sparing of the heart.
Confounding the data is the fact that cardiac, and for that matter pulmonary, toxicities attributed to irradiation are late effects of RT and the true clinical presentation may lag decades behind the radiation treatments. 17 Clearly, the improvements in techniques have paralleled decreases in late complications such as cardiac morbidity. Risk from death from ischemic heart disease associated with radiation for breast cancer has substantially decreased over time. 15 However, the improvements in radiotherapy techniques have been paralleled by the integration of known cardiotoxic agents in the management of breast cancer. For instance, anthracyclines are associated with dose-dependent acute cardiotoxic side effects including: pericarditis, myocarditis, left ventricular dysfunction, and arrhythmias. 18 Delayed effects of anthracyclines include congestive heart failure and systolic dysfunction. 19 There are reports that the use of concurrent doxorubicin-based chemotherapy and radiotherapy do indeed increase the risk of long-term cardiac sequelae. 20, 21 Trastuzumab, a humanized monoclonal antibody to HER2/ErbB2, has been successfully integrated into the management of all stages of breast cancer in patients who overexpress the product of the Her2/neu gene. Although the mechanism of its effects on the heart is not well understood, the use of trastuzumab in several clinical trials has been associated with increased incidence of congestive heart failure. [22] [23] [24] [25] Further, the concurrent use of trastuzumab during radiotherapy has resulted in significant decrease in left ventricular ejection fraction. 26 The use of concurrent trastuzumab and anthracyclines, a common combination used in breast cancer, is also associated with increased cardiovascular morbidity than the use of trastuzumab alone or in combination with other agents such as paclitaxel. 27 As the clinical implications of left-sided breast irradiation are long delayed, with respect to the treatment interval, there has been a movement toward cardiac testing to evaluate the effects of radiation on the heart to look for effects that predate the realization of the potential cardiogenic phenotype created as a result of cardiac radiation exposure. In one such study, patients receiving left-sided adjuvant radiation for breast cancer had detectable SPECT scan changes evident 3 to 6 years post-RT. 8 In another study, Correa et al 28 showed that, at a follow-up at 12 years, there was a statistically significant higher prevalence of stress test abnormalities found among left-side (27 of 46; 59%) versus right-side irradiated patients and, further, there was a skewing of abnormal cardiac catheterizations along the distribution of the left anterior descending artery. Such studies uniformly recommend that, "every effort should be made to minimize incidental irradiation of the heart while maintaining adequate coverage of target volumes." 8 More recently, however, there has been randomized phase III trial data reported in a study designed to assess changes in cardiac perfusion, as measured by SPECT, in women randomized to left chest wall or breast irradiation with or without ABC. The findings show, quite unexpectedly, that there was significant worsening of apical cardiac perfusion 6 months postradiation in patients receiving ABC treatments compared with those treated with FB techniques. 29 Two plausible explanations for these phenomena include the fact that the cardiac vasculature is far more sensitive to lower doses of radiation or that mDIBH induces a conformational change in the heart, uncovering sensitive apical segments (R. Zellers, Oral communication, October 2010). Nonetheless, long-term follow-up on this cohort is necessary to help resolve this issue.
Despite significant improvements in the technical aspects of radiation delivery in recent years, it remains technically "challenging" to comprehensively irradiate the entire cancer breast/chest wall and/or regional lymphatics (internal mammary nodes) for many left-sided breast cancer patients, without compromising target volume coverage and by avoiding the heart. A recent CT planning study of optimized contemporary RT techniques, aiming to irradiate the chest wall and the regional nodes, showed that none of these methods was able to attain this goal in a satisfactory manner. However, it did appear that the use of partially wide tangent fields did result in the lowest heart V 30 . 30 Further, decreases in heart dose have been achieved through the use of 3D conformal and best yet by intensity-modulated approaches. 31 An effective older approach to reduce cardiac radiation exposure is simply to alter the patient's treatment position. Canney et al 32 and Hurkmans et al 33 both reported a reduction in the irradiated volumes of both the heart and lung with the use of a simple forearm support instead of the conventional "L-bar" support. At our institution, an Alpha Cradle immobilization system is used, which more closely produces an effect that resembles that of the forearm support than the "L-bar" support. However, our experience with tangential treatment suggests that, for some patients, portions of the heart will still remain in the field during FB, which cannot be avoided solely by setup modification.
As mentioned above, methods of IMRT have also been exploited in planning studies to improve sparing of the heart. Unfortunately, these IMRT plans are generally complex, requiring the use of additional gantry angles that can potentially increase the dose to the contralateral breast [34] [35] [36] and other normal tissues (some not typically included in treatment plans). These complex treatments can also require lengthy delivery times and attention must be given to ensure that the patient setup remains stable. In addition, the effects of setup error and breathing motion on the dosimetry of these IMRT deliveries have not been studied for determining the appropriate treatment margin.
We also show that the mDIBH technique significantly decreases the dose to the ipsilateral lung. This seems counterintuitive, as there would be more lung within the tangential beam when the heart moves out of the treatment field during mDIBH. However, it has been previously shown that the use of deep inspiration breath-hold technique in breast cancer patients can reduce the mean lung dose by 15% and the lung V 20 by 17%, when compared with FB techniques. 37 These results are comparable with reductions seen in the current study. It is believed that deep inspiration breath-hold technique reduces ipsilateral lung dose by inflation, so that less tissue remains in the irradiated region and that modern planning systems can sufficiently account for such complex computations. 37 In this paper, we present our routine integration of mDIBH with an ABC device in the treatment of patients with early-stage, left-sided breast cancer. In addition, we have combined our ABC procedure with our "step-and-shoot" IMRT method designed primarily to improve homogeneity in the target volume. 11 We currently aim to treat all of our patients less than 60 years old having left-sided lesions with mDIBH, of which >95% can tolerate the breath-hold well enough to complete the ABC treatments. We have shown that our technique has significantly decreased the volume of heart treated, mean heart dose, and all other dosimetric parameters evaluated. A large majority of our patients also received potentially cardiotoxic chemotherapy. Further, the ABC plans allowed for reductions in ipsilateral lung dose and volume. The treatments are well tolerated by all the patients who complete the practice sessions during the planning process. The purpose of our study was to present the dosimetry and feasibility of the routine integration for ABC techniques for patients receiving adjuvant radiation for left-sided breast cancer, and not a study to show the decreased cardiac morbidity associated with the adoption of such techniques. However, this cohort will undoubtedly need to be followed to assess cardiac toxicities compared with the historic controls.
In our present study, we specifically have not presented data pertaining to Normal Tissue Complication Probability (NTCP). First, the true NTCP for the small volumes of heart irradiated is uncertain. 38 Second, some preliminary anatomic data 39 suggest that volumes of heart irradiated with "standard techniques" may involve more critical structures such as the coronary vessels. Third, most NTCP models use pericarditis as an endpoint and do not consider the effects of cardiotoxic drugs such as the anthracyclines and trastuzumab. As a result, NTCP may underestimate the true risk of long-term cardiac disease for breast patients treated with combined radiotherapy and chemotherapy. 
CONCLUSIONS
Reductions in the percentage of the heart receiving 30 Gy can be achieved in patients with left-sided breast cancer using an ABC device to immobilize lung volume at mDIBH. In addition, reduction in lung dose parameters can also be achieved. The technique is simple, well tolerated by patients, and can be implemented for routine use in a busy clinic. The routine integration of this experience suggests that mDIBH, using an ABC device, may provide one of the most promising methods of improving the efficacy of external beam radiation therapy, for patients with left-sided breast cancer. Long-term follow-up is needed to determine the clinical outcomes associated with decreased dose to the heart.
